ClinicalTrials.gg
Active, not recruitingNCT03178617Updated Oct 29, 2026

High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma

An interventional study of Educational Intervention and Educational Intervention in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Lymphoblastic Lymphoma, sponsored by City of Hope Medical Center. Active, not recruiting at 3 sites in United States. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center — 10 open to participants now, 28 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · City of Hope Medical Center.

Enrollment
5th of 50
214 · median 32
Started
2017
the only one that year
No phase
8 of 55
none open now
Primary completion
2027-10
later than 18 of 27 live
Registered
32nd of 55
by date

Among the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, this one is the 5th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2017, is one of 8 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 32nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 5 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This randomized clinical trial studies how well a high-intensity intervention parenting program works in improving learning and school functioning in Latino children with acute leukemia or lymphoblastic lymphoma. A high-intensity intervention program may help doctors to see whether training parents or caregivers in specific parenting skills and "pro-learning" behaviors will result in better learning and school outcomes for Latino children with acute leukemia or lymphoblastic lymphoma. It is not yet known if a high-intensity intervention program is more beneficial than a standard of care lower intensity parenting intervention.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the effectiveness of an enhanced parenting intervention, high-intensity intervention program (HIP), on pediatric cancer survivors' learning and school health-related quality of life (HRQOL) outcomes up to 12 months post enrollment.

II. Determine the effectiveness of HIP on the "pro-learning" efficacy of parents of pediatric cancer survivors up to 12 months post enrollment.

III. Examine the extent to which the parent's increases in personal efficacy and use of "pro-learning" behaviors correlate with the child's school HRQOL and academic performance.

IV. Obtain preliminary data on the relationships between family stress and the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) with neurocognitive and health-related quality of life (HRQOL) outcomes in Latino children treated with CNS-directed therapies for cancer.

V. Conduct preliminary analysis on the interaction between family stress and the BDNF Met polymorphism when predicting cognitive and HRQOL outcomes in Latino children treated for cancer.

EXPLORATORY OBJECTIVES:

I. Explore the associations between neurocognitive performance and polymorphisms in candidate genes previously reported to explain cognitive variability in childhood cancer survivors (e.g., the catechol-O-methyltransferase Val158Met polymorphism and the nitric oxide synthase [NOS3] 894T allele) or involved in the stress response (e.g., the Serotonin transporter rs25531 and the Glucocorticoid receptor rs6190).

OUTLINE: Parents or caregivers are randomized to 1 of 2 arms.

ARM I: Parents or caregivers attend standard of care lower intensity intervention program (LIP) consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.

ARM II: Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.

After study enrollment, patients are followed up for 12 months.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Lymphoblastic Lymphoma
  • Acute Leukemia
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PARENT/CAREGIVER: Adult primary caregiver of children treated for leukemia or lymphoblastic lymphoma (LL) and daily contact with the child
  • PARENT/CAREGIVER: One or both parents self-identify as Hispanic/Latino and the primary participating parent/caregiver is monolingual or bilingual Spanish speaking
  • CHILD: Children treated for acute leukemia (e.g. acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers
  • CHILD: Child has completed cancer treatment and is up to 10 years post-treatment
  • CHILD: Child understands English and is enrolled in school (but can be bilingual)

Exclusion criteria

Exclusion Criteria:

  • History of major psychiatric condition (e.g. psychosis) in parent or child; severe neurodevelopmental disorder in child (e.g. Down's syndrome)
  • Recent or current participation in educational/behavioral intervention study with similar focus
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Active comparator
    Arm I (standard of care LIP)

    Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.

    Other: Educational Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Arm II (HIP)

    Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.

    Other: Educational Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • OtherEducational Intervention

    Attend standard of care LIP

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherEducational Intervention

    Attend HIP

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in child's health-related quality of life school functioning

    Measured by the parent-reported Pediatric Quality of Life Inventory school domain.

    Time frame: Baseline up to 12 months

  2. Change in parental efficacy

    Measured by the Efficacy scale from the Parent Knowledge, Beliefs and Behaviors Questionnaire-3rd Revision (PBQ-R3).

    Time frame: Baseline up to 12 months

Secondary outcomes

  1. Objective academic performance (Child)

    Measured by WIAT: reading and math scores and classroom grades from school report cards.

    Time frame: Up to 12 months

  2. Attention performance (Child)

    Measured by the Conners Parent Report Attention subscale.

    Time frame: Up to 12 months

  3. Frequency of pro-learning behaviors (Parent)

    Measured by PBQ-R3 Behaviors Scale.

    Time frame: Up to 12 months

  4. Frequency of pro-learning behaviors (Parent)

    Measured by the Parents' weekly time spent with child in pro-learning behaviors and activities.

    Time frame: Up to 12 months

  5. Knowledge of pro-learning parenting (Parent)

    Measured by PBQ-R3 Knowledge scale.

    Time frame: Up to 12 months

  6. Children's scores on other neurocognitive tests as assessed by learning, memory, and processing speed

    Time frame: Up to 12 months

  7. Parental reports of their children's HRQOL as measured by the PedsQL parent proxy questionnaire

    Time frame: Up to 12 months

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Oct 2027, 119 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 119 months is above that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2017
First posted
Jun 7, 2017
StartActual
Oct 12, 2017
Primary completionEst.
Oct 11, 2027was Oct 2026
CompletionEst.
Oct 11, 2027was Oct 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 27, 2026→Oct 11, 2027
Oct 29, 2026
Study completion
Oct 27, 2026→Oct 11, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Oct 27, 2026→Oct 11, 2027
    Study completion Oct 27, 2026→Oct 11, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03178617
Responsible party
Sponsor
First posted
Jun 7, 2017
Start date
Oct 12, 2017
Primary completion
Oct 11, 2027 (estimated)
Completion
Oct 11, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Sunita Patel
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion